Abstract| Volume 23, ISSUE 3, PB16-B17, March 2022

Comparison of Preparation Times and Cost for Compounded, Outsourced and Premixed Vancomycin Products in a Long-Term Care Pharmacy

      Multiple drug resistant organism (MDRO) infections are increasingly being treated in post-acute long-term care (PA-LTC) settings, due to high costs associated with treating MDRO in the hospital. While MDRO therapies are increasingly given in PA-LTC settings, studies suggest PA-LTCs may also be a reservoir of MDROs, perhaps more so than hospital settings. Intravenous antimicrobial agents effective against MDRO, such as vancomycin, must increasingly be provisioned to PA-LTC settings, but preparation time and cost of provisioning vancomycin is not well characterized in the literature.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect